Trial Profile
An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects With Type 2 Diabetes Mellitus
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Albiglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 13 Feb 2018 Status changed from completed to discontinued as a result of GSK business considerations and not due to quality, safety or efficacy concerns with any albiglutide formulations or study conduct
- 20 Feb 2017 Status changed from active, no longer recruiting to completed.
- 02 Feb 2017 Planned End Date changed from 1 Nov 2017 to 1 Feb 2017.